7827HanchorBio Inc.

🇹🇼 Tayvan Borsası
149.50
TWD
Analysis Scores
Lothien Robustness Score?
31/100
Weak
Neden bu skor?
Damodaran ?
18/100
DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
82/100
Piotroski ?
3/9
Weak
Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Graham ?
Negatif HBK
Company is loss-making (EPS = -4.0907 TL) — Graham formula requires positive earnings
Active Metric?
1/4
Confidence?
48%
Lothien Robustness Summary
25/100
Lothien Sağlamlık: Çok Zayıf (25/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Olumlu | Uzun Vade: Nötr | Pozitif: 4 | Negatif: 5 | Nötr: 2
Net Zarar
Son çeyrekte -NT$251M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+8.3). İstikrarlı seyir.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-86.4 düştü. Uzun vadede endişe verici.
3 Çeyrek Üst Üste Düşüş
Son 3 çeyrek üst üste kâr düşüyor. Aşağı trend endişe verici. Sonraki çeyreğe dikkat.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından NT$1.6B fazla. Borç riski düşük.
Güçlü Likidite
Cari oran 4.09x — kısa vadeli borçları rahat karşılıyor.
Borç Hızla Artıyor
Toplam borç çeyreklik %+40.8 arttı. Finansman maliyetleri yükselir.
Yüksek PD/DD
PD/DD: 16.00. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Negatif ROE
ROE: %-65.3. Şirket özsermayesini eritiyor.
Özkaynak Büyümesi
Özkaynak çeyreklik %+208.9 arttı. Şirket içsel birikimle güçleniyor.
Sonraki Çeyrek: Artış Beklentisi
Pusla tahminine göre bir sonraki çeyrekte kâr %+49.4 artabilir (-NT$251M → -NT$127M).

Data date 2026-10-22 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-22
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
252 days
Annual Volatility ?
%56.7
VaR 95% ?
%5.51
daily max loss
VaR 99% ?
%7.95
daily max loss
CVaR 95% ?
%6.61
expected loss (tail)
Max Drawdown ?
%27.8
03.03.2026 → 31.03.2026
Skewness ?
1.07
Parametrik%5.51
Historik%4.73
Cornish-Fisher%4.13
Return Distribution
Valuation
Potential?
-36.0%
ROIC ?
-39.6%
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/6
Net kâr çeyreklik %+8.3 artarak -251.0M TWD oldu
Yıllık net kâr %-86.4 geriledi
Brüt kâr marjı düşük: %6.5
Net kâr marjı negatif: %-2630.5 — zarar ediyor
FAVÖK çeyreklik %+19.5 büyüdü (-250.3M TWD)
FAVÖK marjı düşük: %-2623.0
Toplam borç %+40.8 arttı → 140.1M TWD
Net nakit pozisyonunda: -1.6B TWD (borçsuz)
Borç/Özkaynak oranı düşük: 0.11x
Cari oran güçlü: 4.09x — yükümlülükler rahat karşılanıyor
Nakit %+115.5 arttı → 1.8B TWD
İşletme nakit akışı negatif: -236.3M TWD
Serbest nakit akışı negatif: -242.3M TWD — yatırımlar nakdi aşıyor
ROE negatif: %-18.9 — zarar var
ROA düşük: %-12.9
Toplam varlıklar %+102.0 büyüdü → 1.9B TWD
Özkaynak %+208.9 arttı → 1.3B TWD
İşletme kârı negatif: -273.6M TWD — faaliyet zararı
Faiz gideri: 711,000 TWD
Ödenmiş sermaye: 140.0M TWD
Net işletme sermayesi pozitif: 1.4B TWD
İşletme sermayesi değişimi: %+177.2
Yoğun yatırım dönemi: CAPEX/Hasılat %62.5 (6.0M TWD)
Son 3 çeyrek ardışık zarar
Fiyat TRAMA-99 üzerinde: %+16.3 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 128.56 TWD
Likit varlık ağırlığı yüksek: Dönen varlıklar toplam varlıkların %93'i
Fundamental & Technical Analysis
Profitability
Net Profit Margin %-2630.5
Net profit margin %-2630.5 — loss period.
ROE - Return on Equity (TTM) %-65.3
ROE %-65.3 — negative return on equity.
EBITDA Margin %-2623.0
EBITDA margin %-2623.0 — operational loss.
Gross Profit Margin %6.5
Gross profit per revenue %6.5. Evaluate relative to sector.
Free Cash Flow Margin (TTM) %-41.6
TTM Free Cash Flow is %-41.6'i. Negative FCF — company consuming cash.
Valuation
P/B Ratio 16.00x Sector: 3.85x
PD/DD 16.00x — sector median's %316 above. Expensive book value.
Indebtedness
Current Ratio 4.09x
Current ratio 4.09x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity 0.11x
Low leverage — majority of assets financed by equity.
Interest Coverage -210.2x
Interest coverage -210.2x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %-86.4
Loss %86.4 increased — losses deepening.
Score Explanations
Lothien Robustness
31/100
Weak robustness (31/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Weak
Potential
-36.0%
Minus %36.0 expected value (96.32) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 37.62
Damodaran Valuation
18/100
Very Weak
Dalio Risk Analysis
82/100
Low debt risk (82/100). Interest coverage ratio -210.2x — weak, fragile.
Leverage: 95/100 | Debt Service: 100/100 | Quality: 17/100
ROIC - Return on Capital
%-39.6
ROIC (%-39.6) cost of capital (10.9%) below → destroying value.
WACC: %10.9
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
3/9
Weak Piotroski (3/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Weak
Graham Intrinsic Value
—
Company is loss-making (EPS = -4.0907 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
16.00x vs 3.85x
Compared to sector %316 more expensive (by book value)
ROIC vs WACC
%-39.6 vs %10.9 WACC
ROIC 50.4 bps below cost of capital
TRAMA-99 Trend — Strong Uptrend
Price (149.50), TRAMA-99 line's %16.3 above. Strong uptrend continues. Technical momentum positive.
Price:: 149.50
TRAMA: 128.56
Difference: %+16.3
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
7827 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.